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Implantable cardioverter deﬁbrillators (ICDs) have become very useful for patients with a high risk of
sudden cardiac death, based on the results of several clinical trials. Although ICDs can improve survival
when used in patients with heart failure (HF) and reduced left ventricular (LV) function, a recent sub-
analysis of major clinical trials regarding ICDs has revealed that ICD shock is associated with worsening
HF or increase in mortality. ICD settings must be programmed appropriately, guided by clear evidence,
to avoid unnecessary and inappropriate shocks. We discuss the beneﬁts and pitfalls of ICD program-
ming, such as tachycardia pacing, detection intervals, detection rates, and discriminators, to offer
programming tips in this review.
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Several clinical trials [1–4] such as MADIT II [3] and SCD-HeFT
[4], have shown strong evidence regarding implantable cardio-
verter deﬁbrillator (ICD) use in patients with a high risk of sudden
cardiac death. Based on this evidence, the American College of
Cardiology/American Heart Association/Heart Rhythm Society
2008 guidelines [5] and Japanese Circulation Society 2006 Guide-
lines for Non-Pharmacotherapy of Cardiac Arrhythmias, which
was revised in 2011 [6], recommend ICD indications for primary
prevention to include patients with ischemic or non-ischemic
cardiomyopathy, a left ventricular (LV) ejection fraction r35%,
and New York Heart Association (NYHA) function class III or IVrt Rhythm Society. Published by E
: þ81 6 6872 7486.Since the publication of these guidelines, more than 4000 patients
have undergone implantation of ICD every year in Japan (Fig. 1).
Although ICD improves survival when used in patients with heart
failure (HF) and reduced LV function, a recent sub-analysis of
major clinical trials of ICDs has revealed that ICD shock is
associated with worsening HF or increase in mortality [7–10].
Accordingly, it is important to avoid ICD shock, particularly
inappropriate shock, in patients with HF and reduced LV function.2. Incidence of ICD shocks and association with mortality
Current data suggest that about one third of HF patients with
ICD for primary prevention receive ICD shock during their follow-
up periods (Fig. 2). The MADIT II study showed that 20% of study
subjects received ICD shock therapy with an annual shock rate of
5.6% and the incidence of inappropriate shock was 27%, with anlsevier B.V. All rights reserved.
Fig. 1. Annual implantation numbers for ICDs and CRT-Ds in Japan. The annual
implantation numbers for ICDs and CRT-Ds have been increasing rapidly, and recently,
more than 4000 patients have undergone ICD implantation every year in Japan.
Fig. 2. Incidence of total and inappropriate shocks in the MADIT II, SCD-HeFT, and
ALTITUDE studies. Large trials such as MADIT II, SCD-HeFT, and ALTITUDE, have
shown that the occurrence of both inappropriate and total ICD shocks is high.
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appropriate shock was 21% of the ICD arm at 45 months and the
incidence of inappropriate shock occurred in 17% of the ICD arm.
After an ICD shock, either appropriate or inappropriate, it was
reported that hospitalization for HF events and mortality rate
increased. Moss et al. reported that mortality was increased
3-fold with frequent hospitalization for HF after an appropriate
ICD shock and the survival rate after the ﬁrst appropriate ICD
shock was 80% at 1year, which was signiﬁcantly lower compared
with survival without ICD shock [7]. Moreover, the occurrence of
an inappropriate ICD shock was associated with a hazard ratio for
mortality of 2 [8]. Based on sub-analysis of the MADIT II study,
ICD shock therapy was associated with a 39% increased risk of a
ﬁrst hospitalization for HF and a 58% increase in recurrent
admission for HF [9]. In addition, according to the SCD-HeFT
study, patients receiving an appropriate ICD shock had a 5-fold
increase in risk of mortality and patients receiving an inappropri-
ate ICD shock had a 2-fold increase in risk of mortality; these
results are similar to the MADIT II sub-analysis data [10]. Based
on these data, therapeutic shocks for spontaneous ventricular
tachyarrhythmia are at increased risk. However, an adverse
prognosis after shocked spontaneous ventricular tachyarrhythmia
can only be related to underlying heart disease. As for inappropri-
ate ICD shock, in the ALTITUDE study, which included 28,000
patients for primary prevention, inappropriate shock for sinus
tachycardia or for noise oversensing was unrelated to increased
mortality (HR 0.97; 95% CI 0.68–1.37 and HR 0.91; 95% CI 0.50–
1.67, respectively) after adjustment for age, sex, and implantation
data [11]. Underlying cardiac disease can cause ventricular
arrhythmias or atrial ﬁbrillation, in contrast to the shocksthemselves, leading to increased mortality. Although ICD shocks
in normal rhythm have adverse effects in experimental condi-
tions, such as electrical shock trauma of irreversible electropora-
tion of the cell membrane [12–14], Bhavnani et al. reported that
there was no correlation between ICD shock delivered against
induced ventricular arrhythmias and increased risk of all-cause
mortality and hospitalization for HF, compared with patients
without induction of ventricular arrhythmia; they concluded that
ICD shocks for induced ventricular arrhythmias did not increase
the risk of mortality or HF hospitalization signiﬁcantly [15]. There
is a room to argue whether correlation between ICD shocks and
subsequent mortality is due only to a patient’s underlying heart
disease or whether ICD shocks themselves have an independent
causal role. However, we must reduce ICD shocks as much as
possible because they induce adverse psychosocial consequences,
such as unpleasant anxiety and anticipation of the next shock.3. Beneﬁts and tips for antitachycardia pacing
To reduce ICD shocks, antitachycardia pacing (ATP) for termi-
nating lethal ventricular tachyarrhythmias must be programmed.
There are 2 main types of ATP: burst (scan) pacing and autodecre-
mental overdrive pacing (ramp pacing). Programming ATP is
common for ventricular tachycardia (VT) but there are a few data
regarding detailed settings. With regard to the different types of
pacing (burst pacing or ramp pacing), there were no signiﬁcant
differences in terminating VT episodes with cycle length (CL) more
than 320 ms between burst pacing and ramp pacing [16,17];
however, in the case of fast VT episodes with CL between 240
and 320 ms, burst pacing was more effective for terminating VT
episodes compared with ramp pacing [18]. Many episodes labeled
by ICD as ventricular ﬁbrillation (VF) are sometimes rapid mono-
morphic VT, particularly when the CL of VT was between 240 and
320 ms. Wathen et al. reported that an ATP setting with an 8-pulse
burst with pacing train at 88% of VTCL was successful in terminat-
ing rapid VT with CL less than or equal to 320 ms in 72% of study
subjects [19]. Interestingly, the success rate of burst pacing against
rapid VT was higher with 2 sequences compared with only one
sequence [20]. The second sequence terminated 35% of rapid VT.
Moreover, we cannot conclude that ATP was not effective after
failing to terminate rapid VT because one failure of an ATP
sequence did not predict subsequent failure; thus ATP should be
set for rapid VT at all times. According to the number of stimuli and
coupling intervals, Peinado et al., compared 4 settings, including
burst CL at 91% or 81% of VTCL with 7 or 15 stimuli, and reported
that 15 stimuli with a burst CL at 91% of VTCL was the most
effective in terminating VT [21]. However, a recent report of the
ADVANCED-D trial suggested no signiﬁcant differences between
groups with 8 stimuli and 15 stimuli, with regard to terminating
VT with a CL between 240 to 320 ms by burst pacing [22]. In
cardiac resynchronization therapy devices with deﬁbrillators (CRT-
Ds), we can select the pacing mode BiV (right ventricular [RV]
pacing with simultaneous LV pacing) or RV only pacing, as ATP in
some devices. Gasparini et al. reported that the efﬁcacy of the ﬁrst
ATP in terminating any VT was similar in both groups of BiV ATP
and RV only ATP [23]. However, sub-analysis revealed that BiV ATP
was more effective for fast VT with CL between 240 and 320 ms in
patients with ischemic heart disease compared with RV only ATP.
Based on these data, we should select BiV ATP, particularly in
patients with ischemic heart disease.
4. Detection intervals and rates
Non-sustained VTs are often detected by ICD devices, which do
not require ICD therapy, particularly ICD shock. Thus, it is very
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arrhythmias have continued or stopped. Although there is a
recent trend to use a longer detection interval, we should consider
that it is somewhat arbitrary, depending on the patient’s situation
and clinical background, such as ICD indication, baseline LV
function, drug use, etc., because longer detection intervals may
cause arrhythmic syncope or delay therapy. In the PainFree II
study, the detection intervals were set to 18/24 intervals and 34%
of fast VTs were self-terminating in the fast VT zone between
240 ms and 320 ms [19]. Whereas only 1% of ventricular arrhyth-
mias in the VF zone spontaneously terminated using detection
criteria of 12/16 intervals in PainFree I [24]. The PainFree II study
suggests that a longer delay will reduce unnecessary device
detection and therapy. It is, however, likely that a longer duration
of tachycardia detection might increase cases of syncope, result-
ing from delays in therapy. However, longer detection intervals
in the PainFree II study (18/24 intervals) proved safe because
arrhythmic syncope did not increase compared with PainFREE I.
Taking into account recent evidence from the PREPARE [25] and
RELEVANT studies [26], we should adopt a longer duration to
avoid ICD shocks in primary prevention patients with ICD or CRT-
D. The PREPARE study patients were less likely to receive a shock
in the ﬁrst year compared with control patients (9% vs. 17%,
P¼0.01). The incidence of untreated VT and arrhythmic syncope
was similar between the PREPARE study patients and the control
cohort. Likewise, in the RELEVANT study of CRT-D patients with
non-ischemic heart disease and primary prevention, whose
detection interval was much longer in the protect arm (30/40)
compared with the control group (12/16), the total number of
delivered shocks was signiﬁcantly lower in the protect group
compared with the control group (Po0.0001). Moreover, freedom
from the ﬁrst hospitalization for HF was signiﬁcantly better in the
protect group than in the control group (P¼0.038).
As for the detection rate, we should select a different setting
in patients with primary prevention and secondary prevention
because ICD patients with primary prevention experience the
faster lethal arrhythmia with an average rate of 200 beats per
minute [27]. On the other hand, ICD recipients with secondary
prevention indication had the appropriate ICD therapy with an
average of 160 beats per minute [28]. In addition, antiarrhythmic
drugs such as amiodarone are often used in these patients, which
affect the VTCL and induce underdetections (Fig. 3). In fact, the
risk of a slow VT above the tachycardia detection interval was
about 3% (relative risk of 5%) per year during the ﬁrst 4 years after
ICD implantation [29]. HF prior to ICD implantation, spontaneousFig. 3. RR plots during a slow VT above the tachycardia detection interval. RR plots in
detection intervals, which led to delaying therapy. This patient was prescribed amiodamonomorphic VTs, and amiodarone use at discharge, signiﬁcantly
increased the risk of a VT above tachycardia detection interval.
In general, cutoff intervals are often set at the appropriate values
of documented or induced VT intervals with a safety margin of
30–60 ms in ICD patients with secondary prevention indication;
we should therefore take into account of the risk of a slow VT
above the tachycardia detection interval, particularly in ICD
patients taking amiodarone. At this point, we have insufﬁcient
data regarding the relative beneﬁts of a high cutoff rate or a
longer detection interval; however, the MADIT-RIT study is now
ongoing to address this issue, and this may change the settings for
detection in patients with primary prevention indication.5. Discriminators
There are several algorithms for discrimination of supraven-
tricular tachycardia (SVT) and this depends on each company’s
product. We usually program the discriminators up to a rate of
200 beats per minute based on its efﬁcacy, particularly for the
dual chamber system. Friedman et al. reported that more than
10% of inappropriate detection was associated with a heart rate of
over 200 beats per minute [30], and based on this report, the SVT
limit should nominally be set at 230 beats per minute in the most
current product made by Medtronic (ProtectaTM). However, there
is no clear evidence regarding the safety of this high rate setting,
although underdetection of VF using an SVT limit of 200 beats per
minute has not been reported, and we should consider the risk of
overdiscrimination when withdrawing therapies for lethal
arrhythmia events. On the other hand, we must use SVT dis-
criminators in the VT zone because overlapping rates between VT
and SVT were reported in ICD patients [31] and the use of SVT
discriminators reduced inappropriate shocks at 1 year by 20%,
without underdetection [32]. In the VT zone (relatively lower
heart rate), underdetection occurs in less than 1% of true VT
episodes with single or dual chamber discriminators [33–35].6. Recent advances
There are several algorithms developed by suppliers to reduce
mainly inappropriate shocks. Medtronic is one of leading manufac-
turers to address how to reduce inappropriate shocks by developing
new algorithms and to fund all major shock reduction trials. A
new algorithm by Medtronic, ‘‘SmartShockTM Technology’’ includesdicate that VT is terminated by ATP. Note that the initial RR was longer than the
rone.
Fig. 4. New algorithm for T-wave discrimination developed by Medtronic. A new
algorithm for T-wave discrimination was developed to identify T-wave over-
sensing and provide the ability to withhold therapy delivery without compromis-
ing VT/VF detection sensitivity by discrimination of R-waves and T-waves through
differential ﬁltering of the sensing signal.
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from other arrhythmic and nonarrhythmic events. Adaptive PR
Logic plus Wavelet is a famous algorithm that combines mor-
phology and A-V pattern recognition to better discriminate
against all types of SVT. Initially, the use of Adaptive PR Logic
would occasionally misclassify SVT, such as in the case of sudden
onset atrial tachycardia. The addition of Wavelet to the SVT
discrimination logic will allow rhythms that are misclassiﬁed by
Adaptive PR Logic to be reclassiﬁed by Wavelet so that a shock is
appropriately withheld. A new algorithm for T-wave discrimina-
tion has been developed to identify T-wave oversensing and
provide the opportunity to withhold therapy delivery without
compromising VT/VF detection sensitivity by discrimination of
R-waves and T-waves through differential ﬁltering of the sensing
signal (Fig. 4). Lead Integrity Suite is also important, which
consists of RV Lead Noise Discrimination and RV Lead Integrity
Alert [36]. The RV Lead Noise Discrimination algorithm analyzes a
far-ﬁeld electrocardiogram signal to differentiate RV lead noise
from VT/VF. Conﬁrmationþ identiﬁes whether a tachycardia has
been terminated with ATP or spontaneously during the charge
and aborts the shock. Application of ‘‘SmartShockTM Technology’’
to the episode data from the SCD-HeFT study reduced inappropri-
ate ICD shocks by an estimated 59%, which was conﬁrmed by
simulation [37]. Boston adopts further enhanced ﬁltering and
sensing systems with a unique auto gain control and noise
window, which reduced T-wave oversensing in the real world.
Moreover, we can choose between the discriminator algorithm
from Rhythm ID and a classical onset/stability algorithm. Rhythm
ID includes morphology deﬁned as vector timing correlation. If
patients show atrial tachycardia or atrial ﬂutter, we should
choose Rhythm ID because these arrhythmias are usually stable
and have a sudden onset, which suggests difﬁculty in discrimi-
nating SVT from VT by using a classical onset/stability algorithm.
St. Jude Medical has developed ‘‘ShockGuardTM Technology’’,
which includes Decision TX and a new sensing ﬁlter. Decision
TX relies on new nominal settings for detection intervals, detec-
tion rate, and discriminators such as interval stability, AV associa-
tion, and sudden onset, etc. The sensing ﬁlter was also changed to
reduce undersensing of the R-wave and oversensing of the
T-wave. ‘‘ShockGuardTM Technology’’ has shown a reduction of
inappropriate ICD shock as well as unnecessary shocks, and the
Food and Drug Administration in the USA has therefore approvedthis algorithm. Sorin group and Biotronik have also developed
new algorithms to reduce inappropriate ICD shock as well as
unnecessary shocks.7. Conclusion
ICDs have become of great use for patients with a high risk of
sudden cardiac death. However, there are unresolved matters
with regard to ICD, particularly regarding appropriate program-
ming settings to avoid unnecessary shocks and inappropriate
shocks. Taking into consideration the potential risk of under-
detection or detrimental therapy delay for lethal arrhythmias, we
must program ICD settings guided by the available evidence.Conﬂict of interest
All authors have no conﬂicts of interest that should be
disclosed.
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